Skip to content

The predictive value of uterine arterial flow combined with complement system activation factor expression level for preeclampsia in pregnant women with chronic kidney disease

The predictive value of uterine arterial flow combined with complement system activation factor expression level for preeclampsia in pregnant women with chronic kidney disease - Prediction of preeclampsia in pregnant women with chronic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066162
Enrollment
Unknown
Registered
2022-11-25
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease and preeclampsia

Interventions

Patients with chronic kidney disease and pregnancy group:None

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. According to the definition of CKD in KDIGO guidelines, the diagnosis of chronic kidney disease is clear; 2. The diagnosis of intrauterine pregnancy is clear, and the confirmed time of pregnancy is within 11 weeks of pregnancy; 3. 18-45 years old; 4. Recent renal function routine blood test results are available; 5. Be able to follow up the outpatient department of our hospital regularly; 6. Including hypertensive nephropathy and diabetic nephropathy, but without serious diseases of respiratory circulation and other systems; 7. Normal reproductive function; 8. The clinician considers the possibility of continuing the pregnancy; 9. Be willing to sign informed consent; 10. Renal disease was staged from stage I to Stage IIIa.

Exclusion criteria

Exclusion criteria: 1. Multiple pregnancy; 2. Lupus, vasculitis, other systemic immune diseases; 3. Nephropathy caused by abnormal renal structure, urinary obstruction and infectious diseases; 4. The patient or her spouse has hereditary kidney disease (UAKD, Alport, etc.) or other diagnosed hereditary disease; 5. Clinicians evaluate patients with severe kidney disease according to experience (pregnancy with stage ? B and above kidney disease, pregnancy risk is very high), and pregnancy risk is not suitable for pregnancy; 6. Be unwilling or unable to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Placental growth factor;soluble Fms-like tyrosine kinase-1;C3a;C5a;Bb;C4d;membrane attack complex;Uterine artery pulsatility index;Early diastolic notches and S/D values of bilateral uterine arteries;

Countries

China

Contacts

Public ContactYingdong He

Department of Obstetrics and Gynecology, Peking University, First Hospital, Beijing, China

yinghe1234@163.com+86 13810002544

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026